Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma (RCC).

AM0010 is a pegylated humanized IL-10 agonist that is developed to have increased exposure in the blood, Infante explains. Despite successes with PD-1/PD-L1 agents, there are several tumor types that do not have long-term responses with these therapies, demonstrating an ongoing and unmet need. This is also true in cancers that are not immune-sensitive, he adds.

In the phase I study, 33 patients were enrolled in dose-escalation cohorts, where solid tumor responses were observed in uveal melanoma and RCC. In an expansion cohort, researchers enrolled 18 more patients with RCC, totaling 19 patients who received 20 mg/kg of AM0010. Four patients did not go on to re-staging studies. Of these 15 patients, there were 4 total partial responses, Infante adds.

Videos

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Dr. Infante on AM0010 in Patients With RCC

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact of avelumab on the treatment of patients with ovarian cancer.

An upside to treating ovarian cancer, Infante explains, is that patients often respond to several of the approved therapies. However, these are often transient responses that become less durable over time, while tumors become more refractory.

Infante discusses the potential impact of avelumab in treating this disease based off of findings from a phase Ib, open-label expansion trial, which demonstrated that the drug was well-tolerated and had complete and atypical responses in patients who had four prior lines of therapy. If further studies demonstrate similar benefit, Infante says researchers should consider moving avelumab up in treatment lines of ovarian cancer.

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer. 


Dr. Infante on Avelumab's Potential in Ovarian Cancer

Jeffrey Infante, MD, director of drug development at the Sarah Cannon Research Institute on the next step in melanoma research.

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Dr. Infante on the Next Step in Melanoma Research

Jeffrey Infante, MD from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma

Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma

Dr. Infante on the Future of BRAF Inhibitors in Melanoma

Jeffrey Infante, MD, director of drug development at the Sarah Cannon Research Institute talks about BRAF mutation testing.

Dr. Infante says that there is a subset of melanoma patients (about half) that have the BRAF mutation. He adds it can be tested easily around the country by multiple labs. If it turns out that a patient has a genetic change that is a BRAF mutation, there are drugs that can help the patient. While the drugs aren't FDA approved yet, there are many trials ongoing where patients can get access to those drugs.

Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing

Jeffrey R. Infante, MD

Articles

Dr. Infante on AM0010 in Patients With RCC

Dr. Infante on Avelumab's Potential in Ovarian Cancer

Dr. Infante on the Next Step in Melanoma Research

Dr. Infante on the Future of BRAF Inhibitors in Melanoma

Dr. Infante Talks About BRAF Mutation Testing